Role of dendritic cells in the induction and maintenance of autoimmune diseases

Immunological Reviews

Volumn 169, Issue , 1999, Pages 45-54

  Ludewig, Burkhard ^a,b   Odermatt, Bernhard ^a   Ochsenbein, Adrian F ^a   Zinkernagel, Rolf M ^a   Hengartner, Hans ^a  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; PEPTIDE;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIABETES MELLITUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOID ORGAN; NONHUMAN; PANCREAS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSGENE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGEN PRESENTATION; AUTOANTIGENS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RATS;

EID: 0032798198     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01305.x     Document Type: Review

References (87)

1. 1. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-280.
2. 2 Sprent J, Lo D, Gao EK, Ron Y. T-cell selection in the thymus. Immunol Rev 1988;101:173-190.
3. + thymocytes controlled by MHC class II gene products. Nature 1988;336:471-473.
4. 4. Lo D, Freedman J, Hesse S, Brinster RL, Sherman L. Peripheral tolerance in transgenic mice: tolerance to class II MHC and non MHC transgene antigens. Immunol Rev 1991;122:87-102.
5. 5. Ferber I, Schonrich G, Schenkel J, Mellor AL, Arnold B, Hämmerling GJ. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994;263:674-676.
6. 6. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409-414.
7. 7. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
8. 8. Rocha B, Tanchot C, von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 1993;177:1517-1521.
9. 9. Alferink J, Tafuri A, Vestweber D, Hallmann R, Hammerling GJ, Arnold B. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998;282:1338-1341.
10. 10. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1972;25:1.
11. 11. Ohashi PS, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-317.
12. 12. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991;65:319-331.
13. 13. Oldstone MB. Molecular mimicry and autoimmune disease. Cell 1987;50:819-820.
14. 14. Oldstone MB. Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. Curr Top Microbiol Immunol 1989;145:127-135.
15. 15. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
16. 16. Di Marzo Veronese F, et al. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. J Exp Med 1996;183:2509-2516.
17. 17. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-1950.
18. 18. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4:781-785.
19. 19. Zinkernagel RM. Immunology taught by viruses. Science 1996;271:173-178.
20. 20. Zinkernagel RM. Virus-induced immunopathology. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven; 1997. p. 163-180.
21. 21. Cole GA, Nathanson N, Prendergast RA. Requirement for θ-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 1972;238:335-337.
22. 57Cr-release assay? J Exp Med 1986;164:1075-1092.
23. 23. Odermatt B, Eppler M, Leist TP, Hengartner H, Zinkernagel RM. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci USA 1991;88:8252-8256.
24. 24. Kagi D, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin -deficient mice. Nature 1994;369:31-37.
25. 25. Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-α/β during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med 1997;185:517-530.
26. + T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med 1998;187:1903-1920.
27. 27. Miller SD, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997;3:1133-1136.
28. 28. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
29. 29. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
30. 30. Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localizalion of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987;166:1654-1667.
31. 31. Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana C. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 1990;145:2833-2838.
32. 32. Moll H. Epidermal Langerhans cells are critical for immunoregulation of cutaneous leishmaniasis. Immunol Today 1993;14:383-387.
33. 33. Spira AI, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-225.
34. 34. Masurier C, et al. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol 1998;72:7822-7829.
35. 35. Kimber I, Cumberbatch M. Stimulation of Langerhans cell migration by tumor necrosis factor alpha (TNF-α). J Invest Dermatol 1992;99:485-505.
36. 36. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM. Systemic lipopolysaccharide recruits dendritic cell progenitors to nonlymphoid tissues. Transplantation 1995;59:1319-1324.
37. 37. DeSmedt T, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184:1413-1424.
38. 38. Ghanekar S, et al. Cytokine expression by human peripheral blood dendritic cells stimulated in vitro with HIV-1 and herpes simplex virus. J Immunol 1996;157:4028-4036.
39. 39. Milone MC, Fitzgerald-Bocarsly P. The mannose receptor mediates induction of IFN-α in peripheral blood dendritic cells by enveloped RNA and DNA viruses. J Immunol 1998;161:2391-2399.
40. 40. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-450.
41. 41. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-850.
42. 42. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997;388:782-787.
43. 43. Pierre P, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997;388:787-792.
44. 44. Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976;117:2233-2238.
45. 45. Gordon RD, Mathieson BJ, Samelson LE, Boyse EA, Simpson E. The effect of allogeneic presensitization on H-Y graft survival and in vitro cell mediated responses to H-y antigen. J Exp Med 1976;144:810-820.
46. 46. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of sell antigens in vivo. J Exp Med 1996;184:923-930.
47. 47. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998;19:368-373.
48. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997;186:2057-2062.
49. 49. Green EA, Eynon EE, Flavell RA, Local expression of TNFα in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998;9:733-743.
50. 50. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297.
51. + T cells. J Exp Med 1987;166:823-832.
52. + T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993;42:44-55.
53. 53. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997;186:989-997.
54. 54. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268:1185-1188.
55. 55. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997;7:727-738.
56. 56. Lo D, Reilly CR, Scott B, Liblau R, McDevitt HO, Burkly LC. Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur J Immunol 1993;23:1693-1698.
57. 57. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β-cell destruction in NOD mice. Diabetes 1994;43:667-675.
58. + macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on α-cell rest? J Autoimmun 1996;9:341-348.
59. 59. Shimizu J, Carrasco-Marin E, Kanagawa O, Unanue ER. Relationship between β cell injury and antigen presentation in NOD mice. J Immunol 1995;155:4095-4099.
60. 60. Clare-Salzler M, Mullen Y. Marked dendritic cell-T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse. Immunology 1992;76:478-484.
61. 61. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999;189:331-339.
62. 62. Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-α in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998;160:3585-3593.
63. + T cells to cause immunopathology. J Exp Med 1998;187:763-774.
64. 64. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998;188:1493-1501.
65. 65. Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J Virol 1998;72:3812-3818.
66. 66. Heath WR, Kurts C, Miller JF, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998;187:1549-1553.
67. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med 1998;188;415-420.
68. 68. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
69. 69. Albert ML, et al. Immature dendritic cells phagocytose apoptotic cells via αβς and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-1368.
70. 70. Ohashi PS, et al. Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-α. J Immunol 1993;150:5185-5194.
71. 71. Melief MJ, Hoijer MA, Van Paassen HC, Hazenberg MP. Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells. Br J Rheumatol 1995;34:1112-1116.
72. 72. Kabel PJ, Voorbij HA, de Haan-Meulman M, Pals ST, Drexhage HA. High endothelial venules present in lymphoid cell accumulations in thyroids affected by autoimmune disease: a study in men and BB rats of functional activity and development. J Clin Endocrinol Metab 1989;68:744-751.
73. 73. Jansen A, Voorbij HA, Jeucken PH, Bruining GJ, Hooijkaas H, Drexhage HA. An immunohistochemical study on organised lymphoid cell infiltrates in fetal and neonatal pancreases. A comparison with similar infiltrates found in the pancreas of a diabetic infant. Autoimmunity 1993;15:31-38.
74. 74. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Insulitis in transgenic mice expressing tumor necrosis factor β (lymphotoxin) in the pancreas. Proc Natl Acad Sci USA 1992;89:10036-10040.
75. 75 Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Transgenic tumor necrosis factor (TNF)-α production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-α and TNF-β transgenic mice. J Immunol 1993;150:4136-4150.
76. 76. Young JW, Steinman RM. The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells 1996;14:376-387.
77. 77. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183-1187.
78. 78. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995;18:86-94.
79. 79. Zitvogel L, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
80. 80. Flamand V, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-610.
81. 81. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-1182.
82. 82. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
83. 83. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA) specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA, Nat Biotechnol 1998;16:364-369.
84. 84. Song W, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186:1247-1256.
85. 85. Specht JM, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213-1221.
86. 86. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
87. 87. Houghton AN. Cancer antigens: immune recognition of self and altered self J Exp Med 1994;180:1-4.